(27 days)
Not Found
No
The summary does not mention AI, ML, or related terms, and the device description focuses on standard imaging system components and capabilities.
No.
The device is indicated for diagnostic and interventional cardiac angiography procedures, which are used for imaging and diagnosis, not for direct therapeutic treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device is "indicated for use in diagnostic and interventional cardiac angiography".
No
The device description explicitly states it is composed of physical components like a C-arm and image acquisition hardware, indicating it is a hardware-based system with integrated software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for "diagnostic and interventional cardiac angiography and optionally, rotational cardiac angiography procedures of human anatomy." This involves imaging the inside of the body using fluoroscopy, which is an in vivo (within a living organism) procedure.
- Device Description: The description mentions components like a C-arm and image acquisition/processing, which are typical of medical imaging systems used for in vivo procedures.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or providing information about a patient's health status based on such analysis, which are the hallmarks of an IVD.
Therefore, this device is a medical imaging system used for in vivo diagnostic and interventional procedures, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Digital Fluoroscopic Imaging Systems are indicated for use in diagnostic and interventional cardiac angiography and optionally, rotational cardiac angiography procedures of human anatomy. It is intended to replace image intensifier fluoroscopic systems in all diagnostic or interventional cardiac angiography procedures. They can be operated in a mobile as well as a fixed site environment.
Product codes (comma separated list FDA assigned to the subject device)
OWB, JAA and OXO
Device Description
The Innova 2000 and 2000S (Mobile version) hereafter referred to as Mobile Innova 2000 and Innova 2000S - are composed of the the same components as the predicate device. The principle system components include a Carm, image acquisition, processing and archiving capabilities. Materials and construction are equivalent to the predicate device and are compliant with UL 2601-1, IEC 60601-1 and associated collateral standards and applicable sections of 21 CFR Subchapter J.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Fluoroscopic X-ray
Anatomical Site
Human anatomy, cardiac
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The devices have been evaluated for electrical, mechanical and radiation safety and conform to applicable medical device safety and performance standards .
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1650 Image-intensified fluoroscopic x-ray system.
(a)
Identification. An image-intensified fluoroscopic x-ray system is a device intended to visualize anatomical structures by converting a pattern of x-radiation into a visible image through electronic amplification. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). An anthrogram tray or radiology dental tray intended for use with an image-intensified fluoroscopic x-ray system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9. In addition, when intended as an accessory to the device described in paragraph (a) of this section, the fluoroscopic compression device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
JAN 1 6 2003
Image /page/0/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "G" and "E" intertwined within a circular border. The letters are stylized and appear to be hand-drawn or calligraphic. The logo is black and white.
GE Medical Systems
P.O. Box 414. W-400 Milwaukee, WI 53201 USA
This 510(k) summary of Safety and Effectiveness informartion is submitted in accordance with the requirements of 21 CFR 807.87(h).
- Submitter: GE Medical Systems PO Box 414 Milwaukee. WI 53201 Contact Person: Larry A. Kroger Senior Regulatory Programs Manager Tel: 262-544-3894; Fax: 262-548-4768 Date: 18 December 2002 Innova 2000 and Innova 2000S (Mobile version) Device Name: Manufacturer : GE Medical Systems Europe 283 rue de la Minière 78530 Buc Cedex. France Distributed by: GE Medical Systems PO Box 414 Milwaukee. WI 53201 Marketed Device: Innova 2000 and Innova 2000S cleared under K022322. Device Description: The Innova 2000 and 2000S (Mobile version) hereafter referred to as Mobile Innova 2000 and Innova 2000S - are composed of the the same components as the predicate device. The principle system components include a Carm, image acquisition, processing and archiving capabilities. Materials : Materials and construction are equivalent to
1
the predicate device and are compliant with UL 2601-1, IEC 60601-1 and associated collateral standards and applicable sections of 21 CFR Subchapter J.
Indications for use: The Digital Fluoroscopic Imaging systems are indicated for use in generating fluoroscopic images of the human anatomy for diagnostic and interventional cardiac angiography procedures. These systems can be operated in a mobile or fixed site environment.
Comparison with
- Predicate Device: The Mobile Innova 2000 and Innova 2000S systems are a modification of, and of comparable type and substantially equivalent to the currently marketed Innova 2000 and Innova 2000S systems cleared under K022322. They have the same technological characteristics, have comparable key safety and effectiveness features, use the same basic design, construction and materials and have the same intended use as the predicate devices.
- Summary of Studies: The devices have been evaluated for electrical, mechanical and radiation safety and conform to applicable medical device safety and performance standards .
- Conclusions : GE Medical Systems considers that the Mobile Innova 2000 and Innova 2000S systems are substantially equivalent to the currently cleared Innova 2000 and Innova 2000S systems. Their intended use and fundamental scientific technology are the same as the predicate devices. The design and development process of the manufacturer conforms with 21 CFR 820 and ISO 9001/EN 46001 quality systems. The devices also conform to applicable medical device safety and performance standards.
2
Image /page/2/Picture/0 description: The image shows the logo for the Department of Health and Human Services. The logo includes the department's emblem on the left and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES" on the right. The emblem is a stylized representation of a human figure.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
Larry A. Kroger, Ph.D. Senior Regulatory Programs Manager GE Medical Systems P.O. Box 414. W-400 MILWAUKEE WI 53201
JUL 30 2012
Re: K024200
Trade/Device Name: Innova 2000 and 2000S (Mobile Version) Regulation Number: 21 CFR 892.1650 Regulation Name: Image-intensified fluoroscopic x-ray system Regulatory Class: II Product Code: OWB, JAA and OXO Dated: December 18, 2002 Received: December 20, 2002
Dear Dr. Kroger:
This letter corrects our substantially equivalent letter of January 16, 2003.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
3
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
STATEMENT OF INTENDED USE
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: Innova 2000 and Innova 2000 S (Mobile version)
Indications for Use
The Digital Fluoroscopic Imaging Systems are indicated for use in diagnostic and interventional cardiac angiography and optionally, rotational cardiac angiography procedures of human anatomy. It is intended to replace image intensifier fluoroscopic systems in all diagnostic or interventional cardiac angiography procedures. They can be operated in a mobile as well as a fixed site environment.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801-109) OR Over-The-Counter Use
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K024200
Concurrence of CDRH, Office of Device Evaluation (ODE)